{"meshTagsMajor":["Immunotherapy"],"meshTags":["Humans","Interleukin-2","Lymphocytes, Tumor-Infiltrating","Antibodies, Monoclonal","Immunotherapy, Adoptive","Interferons","Killer Cells, Lymphokine-Activated","Skin Neoplasms","Vaccination","Immunotherapy","Melanoma"],"meshMinor":["Humans","Interleukin-2","Lymphocytes, Tumor-Infiltrating","Antibodies, Monoclonal","Immunotherapy, Adoptive","Interferons","Killer Cells, Lymphokine-Activated","Skin Neoplasms","Vaccination","Melanoma"],"organisms":["9606","9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Research Support, U.S. Gov\u0027t, P.H.S.","Review"],"abstract":"The growth of melanoma in humans depends not only on the malignant potential of the tumor but also on the patient\u0027s immune response to the melanoma. As a result, a variety of strategies have evolved to treat melanoma by stimulating antitumor immune responses to melanoma. This article reviews the different approaches being taken and the results obtained to date.","title":"Immunotherapy of malignant melanoma.","pubmedId":"1718648"}